Japan’s cost-effectiveness assessment (CEA) panel has approved a revised handling policy for the CEA system for FY2026, with the health…
REGULATORY
Japan to Revamp Scheme for Drug Maker’s Reporting of Supply Concerns in April
The Japanese health ministry now looks set to overhaul the system for pharma company’s reporting of drug supply risks. From April, the regulator will take a two-step approach in the reporting requirement to separately handle supply concerns that might arise…
To read the full story
Related Article
- Japan Kicks Off New Reporting System for “Supply Risk” and “Supply Status”
April 4, 2024
- Health Minister Reaffirms April Start of New Drug Shortage Reporting Scheme
February 28, 2024
- Panel Snubs Outline of Guidelines for Supply Info Reporting, Production Requests Due to Lack of Explanations
December 12, 2023
- MHLW Proposes Posting Reported Drug Supply Concerns on Its Website
November 22, 2023
- New Working Group to Propose Effective Collection and Sharing of Drug Supply Info by March-End
September 12, 2023
REGULATORY
- Govt’s Honebuto Draft Confirms FY2027 Off-Year Drug Price Revision
July 1, 2026
- Govt Presents Growth Strategy Draft Ahead of July Approval
July 1, 2026
- Lower House Clears Immunization Act Revision
July 1, 2026
- LDP Cautious over Ishin’s GDP-Linked Healthcare Spending Proposal
July 1, 2026
- Japan Begins Review of Domestic CGT Seeds with Limited Market Potential
June 30, 2026
Let’s face it: in today’s world, changing jobs is a normal part of a successful career. But if it’s so normal, why does it feel so hard? For many people, the idea of leaving their current role brings a heavy…
Japan’s leading pharmaceutical wholesalers are bracing for a second consecutive year of profit declines, underscoring the growing challenge of generating…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…